Literature DB >> 16899061

Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes.

Ian M Kronish1, Nina Rieckmann, Ethan A Halm, Daichi Shimbo, David Vorchheimer, Donald C Haas, Karina W Davidson.   

Abstract

BACKGROUND: The persistence of depressive symptoms after hospitalization is a strong risk factor for mortality after acute coronary syndromes (ACS). Poor adherence to secondary prevention behaviors may be a mediator of the relationship between depression and increased mortality.
OBJECTIVE: To determine whether rates of adherence to risk reducing behaviors were affected by depressive status during hospitalization and 3 months later.
DESIGN: Prospective observational cohort study.
SETTING: Three university hospitals. PARTICIPANTS: Five hundred and sixty patients were enrolled within 7 days after ACS. Of these, 492 (88%) patients completed 3-month follow-up. MEASUREMENTS: We used the Beck Depression Inventory (BDI) to assess depressive symptoms in the hospital and 3 months after discharge. We assessed adherence to 5 risk-reducing behaviors by patient self-report at 3 months. We used chi2 analysis to compare differences in adherence among 3 groups: persistently nondepressed (BDI < 10 at hospitalization and 3 months); remittent depressed (BDI > or = 10 at hospitalization; < 10 at 3 months); and persistently depressed patients (BDI > or = 10 at hospitalization and 3 months).
RESULTS: Compared with persistently nondepressed, persistently depressed patients reported lower rates of adherence to quitting smoking (adjusted odds ratio [OR] 0.23, 95% confidence interval [95% CI] 0.05 to 0.97), taking medications (adjusted OR 0.50, 95% CI 0.27 to 0.95), exercising (adjusted OR 0.57, 95% CI 0.34 to 0.95), and attending cardiac rehabilitation (adjusted OR 0.5, 95% CI 0.27 to 0.91). There were no significant differences between remittent depressed and persistently nondepressed patients.
CONCLUSIONS: Persistently depressed patients were less likely to adhere to behaviors that reduce the risk of recurrent ACS. Differences in adherence to these behaviors may explain in part why depression predicts mortality after ACS.

Entities:  

Mesh:

Year:  2006        PMID: 16899061      PMCID: PMC1831650          DOI: 10.1111/j.1525-1497.2006.00586.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  45 in total

1.  Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction.

Authors:  R C Ziegelstein; J A Fauerbach; S S Stevens; J Romanelli; D P Richter; D E Bush
Journal:  Arch Intern Med       Date:  2000-06-26

2.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

3.  Even minimal symptoms of depression increase mortality risk after acute myocardial infarction.

Authors:  D E Bush; R C Ziegelstein; M Tayback; D Richter; S Stevens; H Zahalsky; J A Fauerbach
Journal:  Am J Cardiol       Date:  2001-08-15       Impact factor: 2.778

4.  Longitudinal course of depressive symptomatology after a cardiac event: effects of gender and cardiac rehabilitation.

Authors:  Sherry L Grace; Susan E Abbey; Ruxandra Pinto; Zachary M Shnek; Jane Irvine; Donna E Stewart
Journal:  Psychosom Med       Date:  2005 Jan-Feb       Impact factor: 4.312

5.  Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease.

Authors:  Fabrice Bonnet; Kate Irving; Jean-Louis Terra; Patrice Nony; François Berthezène; Philippe Moulin
Journal:  Atherosclerosis       Date:  2005-02       Impact factor: 5.162

6.  Predictors of attendance at cardiac rehabilitation after myocardial infarction.

Authors:  D Lane; D Carroll; C Ring; D G Beevers; G Y Lip
Journal:  J Psychosom Res       Date:  2001-09       Impact factor: 3.006

7.  Symptoms of depression, acute myocardial infarction, and total mortality in a community sample.

Authors:  J C Barefoot; M Schroll
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

8.  Effect of smoking and sedentary behavior on the association between depressive symptoms and mortality from coronary heart disease.

Authors:  Beverly H Brummett; Michael A Babyak; Ilene C Siegler; Daniel B Mark; Redford B Williams; John C Barefoot
Journal:  Am J Cardiol       Date:  2003-09-01       Impact factor: 2.778

9.  The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression.

Authors:  Wayne J Katon; Michael Von Korff; Elizabeth H B Lin; Greg Simon; Evette Ludman; Joan Russo; Paul Ciechanowski; Edward Walker; Terry Bush
Journal:  Arch Gen Psychiatry       Date:  2004-10

10.  Major depression and medication adherence in elderly patients with coronary artery disease.

Authors:  R M Carney; K E Freedland; S A Eisen; M W Rich; A S Jaffe
Journal:  Health Psychol       Date:  1995-01       Impact factor: 4.267

View more
  69 in total

1.  Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome.

Authors:  Ian M Kronish; Nina Rieckmann; Daichi Shimbo; Matthew Burg; Karina W Davidson
Journal:  Am J Cardiol       Date:  2010-10-15       Impact factor: 2.778

2.  Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis.

Authors:  Bruno Kusznir Vitturi; Alexandre In Han Kim; Lucas Pari Mitre; Ada Pellegrinelli; Berenice Cataldo Oliveira Valerio
Journal:  Neurol Sci       Date:  2020-06-26       Impact factor: 3.307

3.  Directionality of the relationship between depressive symptom dimensions and C-reactive protein in patients with acute coronary syndromes.

Authors:  Jonathan A Shaffer; Donald Edmondson; William F Chaplin; Joseph E Schwartz; Daichi Shimbo; Matthew M Burg; Nina Rieckmann; Karina W Davidson
Journal:  Psychosom Med       Date:  2011-06-02       Impact factor: 4.312

4.  Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome.

Authors:  Karina W Davidson; Matthew M Burg; Ian M Kronish; Daichi Shimbo; Lucia Dettenborn; Roxana Mehran; David Vorchheimer; Lynn Clemow; Joseph E Schwartz; Francois Lespérance; Nina Rieckmann
Journal:  Arch Gen Psychiatry       Date:  2010-05

Review 5.  Cardiac Rehabilitation in Patients with Established Atherosclerotic Vascular Disease: New Directions in the Era of Value-Based Healthcare.

Authors:  Karen Aspry; Wen-Chih Wu; Elena Salmoirago-Blotcher
Journal:  Curr Atheroscler Rep       Date:  2016-02       Impact factor: 5.113

6.  Factors associated with objectively measured exercise participation after hospitalization for acute coronary syndrome.

Authors:  Ashley M Goodwin; Andrea T Duran; Ian M Kronish; Nathalie Moise; Gabriel J Sanchez; Carol Ewing Garber; Joseph E Schwartz; Keith M Diaz
Journal:  Int J Cardiol       Date:  2018-09-28       Impact factor: 4.164

7.  The impact of medication nonadherence on the relationship between mortality risk and depression in heart failure.

Authors:  Emily C Gathright; Mary A Dolansky; John Gunstad; Joseph D Redle; Richard A Josephson; Shirley M Moore; Joel W Hughes
Journal:  Health Psychol       Date:  2017-07-20       Impact factor: 4.267

Review 8.  State of the Art Review: Depression, Stress, Anxiety, and Cardiovascular Disease.

Authors:  Beth E Cohen; Donald Edmondson; Ian M Kronish
Journal:  Am J Hypertens       Date:  2015-04-24       Impact factor: 2.689

9.  Adverse hospital events for mentally ill patients undergoing coronary artery bypass surgery.

Authors:  Yue Li; Laurent G Glance; Xueya Cai; Dana B Mukamel
Journal:  Health Serv Res       Date:  2008-07-28       Impact factor: 3.402

10.  The effect of enhanced depression care on adherence to risk-reducing behaviors after acute coronary syndromes: findings from the COPES trial.

Authors:  Ian M Kronish; Nina Rieckmann; Matthew M Burg; Donald Edmondson; Joseph E Schwartz; Karina W Davidson
Journal:  Am Heart J       Date:  2012-10       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.